Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory and Relapsed T Cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchUnknownNCT04626739
What this trial is testing

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Who this might be right for
Refractory Indolent Adult Non-Hodgkin Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 100
Testing effectiveness (Phase 2)Looking for participantsNCT07473167
What this trial is testing

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Who this might be right for
Relapsed Large B-cell LymphomaRefractory Large B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)+3 more
TICAROS Co., Ltd. 98
Not applicableNot Yet RecruitingNCT07008872
What this trial is testing

CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

Who this might be right for
CD7+ LymphomaCD7+ Acute Leukemia
Qi deng 40
Early research (Phase 1)Not Yet RecruitingNCT07335328
What this trial is testing

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

Who this might be right for
B-cell Non Hodgkin Lymphoma
Medical College of Wisconsin 24
Testing effectiveness (Phase 2)Ended earlyNCT01636388
What this trial is testing

Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma

Who this might be right for
Hodgkins Lymphoma
New York Medical College 2
Testing effectiveness (Phase 2)UnknownNCT04231370
What this trial is testing

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

Who this might be right for
NK/T Cell Lymphoma Nos
Beijing Tongren Hospital 20
Early research (Phase 1)Looking for participantsNCT06830031
What this trial is testing

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell-lymphomaDLBCL, Nos Genetic SubtypesFollicular Lymphoma Grade 3B+3 more
Shanghai Exuma Biotechnology Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT04323657
What this trial is testing

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
Non Hodgkin LymphomaAcute Lymphoblastic LeukemiaDiffuse Large B Cell Lymphoma+3 more
TCR2 Therapeutics 6
Early research (Phase 1)Study completedNCT03939026
What this trial is testing

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Who this might be right for
Relapsed/Refractory Large B Cell LymphomaRelapsed/Refractory Follicular Lymphoma
Allogene Therapeutics 50
Very early researchLooking for participantsNCT04227015
What this trial is testing

CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
He Huang 72
Very early researchLooking for participantsNCT06532643
What this trial is testing

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

Who this might be right for
Relapsed/Refractory Lymphoma
Shanghai First Song Biotechnology Co., LTD 9
Not applicableNo Longer AvailableNCT01196208
What this trial is testing

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Who this might be right for
Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin+1 more
Seagen Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT04571138
What this trial is testing

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma

Who this might be right for
LeukemiaLymphoma
Seattle Children's Hospital 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT02790515
What this trial is testing

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Myeloid Sarcoma+4 more
St. Jude Children's Research Hospital 170
Early research (Phase 1)Ended earlyNCT00100152
What this trial is testing

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

Who this might be right for
Leukemia, Lymphoblastic, Acute, T-cellMyelogenous LeukemiaChronic Lymphocytic Leukemia+1 more
Merck Sharp & Dohme LLC 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT04984837
What this trial is testing

Study of Lacutamab in Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T Cell LymphomaRelapse/Recurrence
The Lymphoma Academic Research Organisation 49
Testing effectiveness (Phase 2)Looking for participantsNCT05934513
What this trial is testing

GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc. 95
Not applicableLooking for participantsNCT05620680
What this trial is testing

CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

Who this might be right for
T Lymphoblastic Leukemia/Lymphoma
Shenzhen University General Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06542250
What this trial is testing

Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Who this might be right for
B-cell Malignancies
AstraZeneca 174
Testing effectiveness (Phase 2)Study completedNCT00156013
What this trial is testing

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Lymphoma, B-CellLymphoma, Non-Hodgkin
Oncology Specialists, S.C. 33
Next Page